NLS Pharmaceutics to Proceed with Phase 3 Clinical Program (AMAZE) for Mazindol ER for the Treatment of Narcolepsy Following FDA Review and IRB Approval of the Full Study Protocol

NLS Pharmaceutics, a Swiss clinical-stage biopharmaceutical company, has received approval from the U.S. Food and Drug Administration (FDA) to proceed with its Phase 3 clinical program for Mazindol ER in the treatment of narcolepsy. The full study protocol, called AMAZE, was reviewed by the FDA and also received approval from the independent Institutional Review Board (IRB). This milestone allow..